Search





Search





Travere Therapeutics Provides Update On FDA Advisory Committee Meeting For FILSPARI In FSGS

ReutersSep 10, 2025 11:55 AM

Sept 10 (Reuters) - Travere Therapeutics Inc TVTX.O:

TRAVERE THERAPEUTICS PROVIDES UPDATE ON FDA ADVISORY COMMITTEE MEETING FOR FILSPARI® (SPARSENTAN) IN FSGS
TRAVERE THERAPEUTICS INC - FDA NO LONGER REQUIRES ADVISORY COMMITTEE FOR FILSPARI SNDA REVIEW
TRAVERE THERAPEUTICS INC - FDA PDUFA DATE FOR FILSPARI SET FOR JANUARY 13, 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

What Is Intel, and Is Its Stock Still a Worthwhile Investment?

Intel has survived its near-death experience. While it is no longer the undisputed king, it has become the bedrock of the Western semiconductor supply chain. For investors, INTC is now a play on industrial resilience rather than pure high-growth software.

Intel vs. TSM: Which Semiconductor Stock Looks Like the Better Investment?

TradingKey - Intel Corporation (NASDAQ: INTC) and Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM) are two companies that play crucial roles in the semiconductor market; however, they each have completely different business models.

Precious Metals May Outlook: After U.S.-Iran Conflict Concerns Eased, Will Funds Flow Back to Gold and Silver?

TradingKey - Since April, the precious metals market has continued the weakness seen in March. Spot gold recorded a cumulative decline of nearly 2% in April, while spot silver briefly fell below the $70 mark.

Is SanDisk the Hidden Gem of the AI Boom in 2026? Discover the Potential Risks and Rewards.

TradingKey - SanDisk (SNDK) now represents not just a name for many consumers, but also an investment play on one of the fastest-growing sectors in technology – Artificial Intelligence.

Azure Growth 40%, AI Revenue 37 Billion: Why Did Microsoft Shares Fall Instead of Rise?

TradingKey - On April 29 (ET), Microsoft (MSFT) released its Q3 FY2026 results after the bell. Both revenue and profit exceeded expectations, with Azure growth returning to 40% and annualized AI revenue surpassing $37 billion. Despite this, shares fell more than 3% in after-hours trading and ended t

Featured Tools

marketing_marketsTitle

calendar_economicCalendar

Economic Calendar

search.intelligent.strategy

article_asider_weekly_report

link

SanDisk Surges 8% as Earnings Countdown Begins - Here's What Every Investor Needs to Know

Azure Growth 40%, AI Revenue 37 Billion: Why Did Microsoft Shares Fall Instead of Rise?

Nvidia Stock Prediction: Can NVDA Hit $1,000 by 2030?

Robinhood Slumps 8% After Earnings. Revenue and Profit Both Miss, Market Fears Coinbase May Follow Suit.

GOOGL Vs. MSFT: 2 Monster Stocks to Hold for the Next 5 Years

Tradingkey

Tradingkey

KeyAI

